A Double-blinded, Randomized, Controlled, Single Ascending Dose Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs ASP-5354 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Astellas Pharma Global Development
- 27 Jun 2019 Status changed from recruiting to completed.
- 26 Feb 2019 Planned number of patients changed from 24 to 30.
- 26 Feb 2019 Planned End Date changed from 1 Mar 2019 to 1 Jun 2019.